SpaceX's stock is going public this week and will trade on the Nasdaq exchange under the ticker symbol SPCX. Its valuation will be around $1.75 trillion to start. But regardless of how it performs in its early days, it's fair to say that this is going to be one of the most highly valued stocks on the market. The largest non-financial Nasdaq stocks are added to the Nasdaq-100 index, which the highl...
SpaceX's stock is going public this week and will trade on the Nasdaq exchange under the ticker symbol SPCX. Its valuation will be around $1.75 trillion to start. But regardless of how it performs in its early days, it's fair to say that this is going to be one of the most highly valued stocks on the market. The largest non-financial Nasdaq stocks are added to the Nasdaq-100 index, which the highly popular Invesco QQQ Trust (NASDAQ: QQQ) tracks. With recent rule changes, SpaceX's stock could join the index after just 15 trading days. Should you consider adding the Invesco ETF to your portfolio today, to take advantage of these changes? Image source: Getty Images. Continue reading
Many investors are excitedly waiting for the SpaceX initial public offering (IPO). With its dominance in space launches and Elon Musk's leadership, many investors undoubtedly want to own this stock. Unfortunately, its size presents a challenge. It will debut on the market at an expected market value of just under $1.8 trillion, instantly making it one of the 10 largest publicly traded companies. T...
Many investors are excitedly waiting for the SpaceX initial public offering (IPO). With its dominance in space launches and Elon Musk's leadership, many investors undoubtedly want to own this stock. Unfortunately, its size presents a challenge. It will debut on the market at an expected market value of just under $1.8 trillion, instantly making it one of the 10 largest publicly traded companies. This means for it to become a 10-bagger, it has to reach an $18 trillion market capitalization, a notable feat when no stock has yet reached $6 trillion. This mathematical challenge should have investors looking elsewhere for potential 10-bagger stocks. While no analyst can guarantee a stock will grow that much, these three stand a strong chance of achieving such a milestone. Continue reading
Major earnings expected after the bell on Tuesday include: Cracker Barrel Old Country Store ( CBRL ) Domo ( DOMO ) Casey's General Stores ( CASY ) BARK ( BARK ) Lakeland Industries ( LAKE ) For Seeking Alpha's full earnings season calendar, click here .
Major earnings expected after the bell on Tuesday include: Cracker Barrel Old Country Store ( CBRL ) Domo ( DOMO ) Casey's General Stores ( CASY ) BARK ( BARK ) Lakeland Industries ( LAKE ) For Seeking Alpha's full earnings season calendar, click here .
hapabapa/iStock Editorial via Getty Images In my last article, I rated Advanced Micro Devices, Inc. ( AMD ) stock a Strong Buy with a 2028 price target of $551 and its present value of $388. Earlier than expected, AMD's stock price marked these levels in a matter of a few weeks. The rating was based on AMD’s business shift from a cyclical silicon seller into an AI infrastructure utility. Pointed o...
hapabapa/iStock Editorial via Getty Images In my last article, I rated Advanced Micro Devices, Inc. ( AMD ) stock a Strong Buy with a 2028 price target of $551 and its present value of $388. Earlier than expected, AMD's stock price marked these levels in a matter of a few weeks. The rating was based on AMD’s business shift from a cyclical silicon seller into an AI infrastructure utility. Pointed out its Equity-as-a-Service (EaaS) model (issuing 320 million performance warrants to Meta and OpenAI), the thesis expanded on AMD’s smart move to crowdsource the dismantling of Nvidia’s ( NVDA ) moat. At the same time, AMD’s shift toward agentic AI is pushing its business into an x86 CPU supercycle. Apart from that, the thesis explained how AMD’s chiplet architecture neutralizes custom ASIC risks through mass customization. More so, that article pointed out the main downside risks like a 20% equity dilution overhang, gross margin caps from hyper-scale deployments, US-China regulatory friction, and emerging SRAM-first inference architectures. All in all, that article concluded that AMD’s ecosystem lock-in and guaranteed demand flow advantage far outweigh the short-term margin compression issue. Koyfin Now in this article, I continue to mark a Strong Buy rating for AMD stock based on compute-inversion. To explain more here, agentic AI shifts the true cap from parallel GPUs to highly concurrent serial CPUs. AMD’s 256-core Venice processor aligned its business to capture a disproportionate share of the newly expanded >$120 billion server CPU TAM . Further, AMD's $10 billion move to panel-level EFB packaging bypasses TSMC’s CoWoS capacity chokehold. This move is backing scalable, higher-margin MI450X and Helios rack-scale deployments. The 6-gigawatt semi-custom ASIC deal with Meta ( META ) locks-in utility-scale volume and ticks-up AMD’s open-ecosystem strategy against closed-loop rival comps, like Nvidia. However, I want to point out that there are material risks to this thesis...
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) says that prescriptions for its new oral weight loss therapy, the Wegovy pill, have exceeded 3M in just five months after its U.S. launch, a milestone for a company that is struggling to outshine its rival Eli Lilly ( LLY ) in the lucrative market for obesity drugs. During an R&D event on Sunday, the Danish drugmaker said it achieved...
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) says that prescriptions for its new oral weight loss therapy, the Wegovy pill, have exceeded 3M in just five months after its U.S. launch, a milestone for a company that is struggling to outshine its rival Eli Lilly ( LLY ) in the lucrative market for obesity drugs. During an R&D event on Sunday, the Danish drugmaker said it achieved 1M prescriptions for the Wegovy pill in 10 -12 weeks of its U.S. launch earlier this year and recorded 2M additional prescriptions over the last 10 weeks. “That's in light of competition having arrived in the latter part. So if that is not acceleration, I don't know what is,” CEO Mike Doustdar added. He was referring to Eli Lilly’s ( LLY ) oral weight loss therapy, Foundayo, which entered the market in April. However, U.S. prescriptions for Foundayo have trailed those for the Wegovy pill, according to IQVIA ( IQV ) data sourced by analysts, though the U.S. drugmaker remains head and shoulders above its European rival on Wall Street. Novo ( NVO ) said that more than 80% of new prescriptions for the Wegovy pill were for patients new to the GLP-1 drug class, indicating that its once-daily therapy was expanding the overall market for obesity treatments. Last week, TD Cowen raised its 2030 global sales estimate for GLP-1 drugs to $150B from $139B, citing, among other things, a 14% contribution from oral versions of the drug class. More on Novo Nordisk A/S Novo Nordisk: The Biggest Healthcare Bargain Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript Wall Street Underestimates Novo Nordisk's GLP-1 Comeback Novo Nordisk actively seeking deals to expand pipeline, CEO says Novo Nordisk says oral Wegovy success to soften sales decline